Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
64.3M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
38.1M
-
Shares change
-
+773K
-
Total reported value, excl. options
-
$612M
-
Value change
-
+$42.6M
-
Put/Call ratio
-
1.39
-
Number of buys
-
50
-
Number of sells
-
-33
-
Price
-
$16.05
Significant Holders of Vera Therapeutics, Inc. - COMMON STOCK (VERA) as of Q2 2023
96 filings reported holding VERA - Vera Therapeutics, Inc. - COMMON STOCK as of Q2 2023.
Vera Therapeutics, Inc. - COMMON STOCK (VERA) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.1M shares
of 64.3M outstanding shares and own 59.27% of the company stock.
Largest 10 shareholders include FMR LLC (6.54M shares), COMMODORE CAPITAL LP (5.45M shares), Sofinnova Investments, Inc. (3.47M shares), Kynam Capital Management, LP (3M shares), Carlyle Group Inc. (2.42M shares), BlackRock Inc. (2.17M shares), ORBIMED ADVISORS LLC (1.76M shares), Woodline Partners LP (1.75M shares), Eversept Partners, LP (1.74M shares), and VANGUARD GROUP INC (1.44M shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.